Atos Group ATO
EURONEXT · France · Technology Services
€22.28+1.04 (+4.90%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority r
Atos appoints Paul Potgieter as Head of Middle East & Türkiye Paris, France, September 28, 2026 – Atos today announces the appointment of Paul Potgieter as Head of Middle East & Türkiye (MET), reinforcing the company's commitment to accelerating growth and innovation in Artificial Intelligence, Sovereignty and Cybersecurity across the region. Paul Potgieter joins Atos with more than 24 years of international technology leadership experience, having successfully led large-scale business, digital
Press Release Eviden and AllWayTon partner to bring the first triple-mode FRMCS/5G P/GSM-R smartphones to railway industry The solution combines Eviden’s MCX technology with AllWayTon’s railway smartphones to support the transition from aging GSM-R to FRMCS, the next-generation railway communications Paris, France – September 22, 2026 – Eviden, the Atos Group product brand leading in cybersecurity products, mission-critical systems and vision AI today announces an exclusive partnership with AllW
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.